In this regard, while USP22 has been proposed as a novel therapeutic target based on its oncogenic functions [93,94,95], our work suggests that USP22 inhibition will induce CIN that may promote cancer progression and/or the development of secondary malignancies. The gene discussed is USP22; the disease is cancer.